Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Seloxavir marboxil
- Development stage
- Phase 3
- Lead developer
- Zenshine Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Seloxavir marboxil, also known as ZX-7101A, is an antiviral drug developed by Nanjing Zenshine Pharmaceuticals. It acts as a cap-dependent endonuclease (CEN) inhibitor, targeting the polymerase acidic protein (PA) of the influenza virus. This mechanism prevents viral replication by inhibiting the "cap snatching" process essential for viral gene transcription. The drug is being developed for the treatment of uncomplicated influenza, demonstrating broad-spectrum antiviral activity against both influenza A and B viruses.
- Brand names
- Sebaloxavir Marboxil
- Other names
- 玛赛洛沙韦
02
Targets
CEN (Influenza A virus (2009 H1N1) polymerase acidic protein (PA) endonuclease)p3 (Amyloid-beta p3 fragment)
Beyond the preview
Go deeper on Seloxavir marboxil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Seloxavir marboxil.